Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in Breast Cancer Patients Previously Treated with Endocrine Therapy
A new study presented at the 2024 ASCO Annual Meeting shows that trastuzumab deruxtecan outperforms standard chemotherapy in delaying cancer progression for HR+, HER2-low, and HER2-ultralow metastatic breast cancer patients.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
